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Abstract To characterise the NADH oxidase activity of
both xanthine dehydrogenase (XD) and xanthine oxidase
(XO) forms of rat liver xanthine oxidoreductase (XOR) and
to evaluate the potential role of this mammalian enzyme as
an O2
•– source, kinetics and electron paramagnetic reso-
nance (EPR) spectroscopic studies were performed. A
steady-state kinetics study of XD showed that it catalyses
NADH oxidation, leading to the formation of one O2
•–
molecule and half a H2O2 molecule per NADH molecule, at
rates 3 times those observed for XO (29.2 ± 1.6 and
9.38 ± 0.31 min–1, respectively). EPR spectra of NADH-
reduced XD and XO were qualitatively similar, but they
were quantitatively quite different. While NADH efficiently
reduced XD, only a great excess of NADH reduced XO. In
agreement with reductive titration data, the XD specificity
constant for NADH (8.73 ± 1.36 lM–1 min–1) was found to
be higher than that of the XO specificity constant
(1.07 ± 0.09 lM–1 min–1). It was confirmed that, for the
reducing substrate xanthine, rat liver XD is also a better O2
•–
source than XO. These data show that the dehydrogenase
form of liver XOR is, thus, intrinsically more efficient at
generating O2
•– than the oxidase form, independently of the
reducing substrate. Most importantly, for comparative pur-
poses, human liver XO activity towards NADH oxidation
was also studied, and the kinetics parameters obtained were
found to be very similar to those of the XO form of rat liver
XOR, foreseeing potential applications of rat liver XOR as a
model of the human liver enzyme.
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Xanthine oxidoreductase (XOR), until recently also re-
ferred to as xanthine oxidase (XO), has been the subject of
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many mechanistic, structural and biophysical reviews
[1–4]. Mammalian XOR is the key enzyme in the catabo-
lism of purines, oxidising hypoxanthine to xanthine and
xanthine to the terminal catabolite urate. XOR is a complex
homodimer, containing one molybdopterin, one flavin
adenine dinucleotide (FAD) and two different [2Fe–2S]
centres (named Fe/S I and Fe/S II) per 145-kDa subunit [1].
The mammalian XOR is synthesised as an NAD+-depen-
dent dehydrogenase (throughout the text referred to as
xanthine dehydrogenase, XD) but, although it transfers the
electrons preferentially to NAD+, it can also catalyse
electron transfer to O2. XD can, however, be readily con-
verted to a ‘‘strict’’ oxidase form (named XO), either
reversibly, through oxidation of the cysteine residues 535
and 992, or irreversibly, by proteolysis [5, 6]. The cysteine
oxidation (or proteolysis) causes a conformational change
in the vicinity of the FAD, the site at which O2 and NAD
+
react, increasing the midpoint potential of the flavin moiety
and blocking the access of NAD+ to FAD, but without
disturbing the interactions between O2 and FAD [7].
The reduction of O2, catalysed by both enzyme forms,
yields O2
•– and H2O2, with the stoichiometry of these
reaction products being differentially affected by the form
and the source of the enzyme and by the reactant concen-
trations [8, 9]. Therefore, XOR can act as a source of
reactive oxygen species (ROS) and it is this capacity of
XOR that makes the enzyme the focus of interest in many
recent biochemical and clinical studies. Normal processes
of metabolism continuously form ROS, and many of them
may have useful physiological functions, such as in host
defence against invading pathogens, and as mediators of
signal transduction [10, 11]. Their overproduction, how-
ever, can play a major role in several pathological condi-
tions [12–16]. Moreover, it was recently shown that XOR
can catalyse the reduction of nitrates and nitrites, giving
rise to both •NO [17,18] and peroxynitrite (ONOO–) [19].
This fact further amplifies the physiological and patho-
logical significance of XOR. Unlike NO synthase, XOR
can produce •NO under anoxic conditions and, thus, pro-
mote the •NO-dependent vasodilatation in ischaemic tis-
sues [20]. On the other hand, ONOO–, a powerful oxidant
and destructive agent, which results from the diffusion-
controlled reaction between •NO and O2
•– [21], can be
produced solely by the action of XOR [19]. The XOR-
derived ONOO– has been proposed as a bactericidal agent
in milk and the digestive tract [19].
XOR has a broad specificity for reducing substrates. In
addition to the well-known oxidation of hypoxanthine and
xanthine, XOR also catalyses the oxidation of a wide
variety of aldehydes and substituted pyridines, purines,
pteridines and related compounds, including NADH [22].
The reaction catalysed by XOR can be separated into a
reductive half-reaction and an oxidative half-reaction. The
reducing substrates are oxidised at the molybdenum site,
and the reduction mechanism is thought to be the same for
both XD and XO [1, 7]. The electrons thus transferred from
the substrate to the enzyme are rapidly distributed
throughout the other centres, by intramolecular electron
transfer, according to their redox potentials. In the oxida-
tive half-reaction, electrons are transferred from the FAD
centre to NAD+ or O2 [1, 23]. NADH, although a reducing
substrate, is an important exception, since electron transfer
is achieved through the FAD centre [1].
The present knowledge of XOR biochemistry is mainly
based on the most studied bovine milk XO and, to a lesser
extent, on chicken liver XD. Several studies on bovine milk
XOR and, more recently, on human milk XOR [24], which
enable a direct comparison between XD and XO forms,
have also been performed. In contrast, mammalian liver
enzymes, with much more potential clinical relevance,
have been poorly studied; it being generally accepted that
they have similar kinetics and spectroscopic properties to
those described for bovine milk or with avian origin. This
is not necessarily correct, as it will be later discussed (see
‘‘Discussion’’). In particular, NADH oxidase activity of
mammalian liver XOR has not been studied. The activity
of this NADH oxidase would be of special importance in
ROS-mediated diseases, such as ethanol hepatotoxicity and
ischaemia-reperfusion injury, pathological states in which
an increase in NADH concentration is observed [25–27]
and where the generation of O2
•– and H2O2 would be
greatly amplified. To characterise this potential ‘‘new’’
mammalian liver ROS source, the NADH oxidase activities
of both XD and XO forms of rat liver XOR were studied,
with particular regard to their rates and reaction products.
To accomplish this, in the present work, rat liver XOR
was successfully purified in its XO reversible form and
steady-state kinetics of NADH consumption and O2
•–
production were compared between the XD and XO forms
of the enzyme. In addition, electronic paramagnetic reso-
nance (EPR) spectroscopic studies with dithionite and
NADH-reduced XD and XO were performed. To empha-
sise the differences between milk and mammalian liver
enzymes, the catalytic properties of bovine milk XO to-
wards NADH oxidation were also studied. A parallel study
was carried out with a human liver XO isoform, to compare
its kinetics parameters with those obtained for the rat liver
XO isoform. In addition, the NADH oxidase activity of rat
liver aldehyde oxidase (AO) was also characterised. AO is
structurally very similar to XOR, containing one FAD, two
nonidentical [2Fe–2S] centres and one molybdopterin, in a
homodimeric structure. Both enzymes have broad and
overlapping specificity for reducing substrates but, unlike
XOR, AO cannot be converted to a dehydrogenase form,
being unable to utilise NAD+ as the oxidising substrate
[28].
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Materials and methods
Adult male Sprague–Dawley rats (3–4 months old) were
obtained from the Instituto de Investigação Cientı́fica
Bento da Rocha Cabral (Lisbon, Portugal).
All the reagents were of the highest quality available
and were used as supplied. Horse heart ferricytochrome c,
p-dimethylaminocinnamaldehyde, dithiothreitol, NADH,
NAD+, xanthine, bovine milk XO and bovine erythrocytes
superoxide dismutase were from Sigma Chemical Co.
(Madrid, Spain). All the other reagents were from Merck
(Darmstadt, Germany). NADH, NAD+ and xanthine con-
centrations were determined spectrophotometrically using
e = 6,220 M–1 cm–1 at 340 nm, e = 18,000 M–1 cm–1 at
260 nm and e = 9,300 M–1 cm–1 at 277 nm, respectively.
Activity assays and spectra were recorded using a
PC-linked UV2-100 Unicam spectrophotometer with a
temperature controlled cell unit.
Enzyme assays
XO activity was measured using 20 lM xanthine in
50 mM phosphate buffer pH 7.8, at 298 K, in air-equili-
brated solution, with the production of urate being moni-
tored at 295 nm (e = 9,500 M–1 cm–1). XD activity was
measured using the same assay mixture as described for
XO, plus 85 lM NAD+ and monitoring NADH production
at 340 nm (e = 6,220 M–1 cm–1). One unit of catalytic
activity is defined as the amount of enzyme required to
catalyse the oxidation of 1 lmol min–1 of substrate, under
our experimental conditions. The dehydrogenase-to-oxi-
dase ratio of XOR, as defined by Waud and Rajagopalan
[29], was determined as the ratio of aerobic formation of
urate, measured at 295 nm, in the presence of NAD+ to that
in the absence of NAD+. AO activity was assayed by fol-
lowing the oxidation of 25 lM p-dimethylaminocinnam-
aldehyde at 398 nm (e = 30,500 M–1 cm–1) in 50 mM
phosphate buffer pH 7.8, at 298 K, in air-equilibrated
solution.
Purification of the XO form of XOR and AO
from rat liver
XOR, in its reversible XO form, and AO were purified
from rat liver as previously described by Maia and Mira
[30]. Briefly, the rat liver homogenate was fractionated by
heat denaturation and by ammonium sulfate precipitation
to give a crude extract containing both enzymes. This ex-
tract was chromatographed on a hydroxyapatite column
(Bio-Rad, CA, USA) that completely separated AO from
XO. Further purification of XO forms by anion-exchange
chromatography on a Q-Sepharose Fast Flow column
(Pharmacia Biotech, Uppsala, Sweden) resulted in a highly
purified (about 1,200-fold) preparation, with a specific
activity of 3.5–3.7 U mg–1. AO was purified about 1,000-
fold, with a specific activity of 3.4–3.6 U mg–1, by affinity
chromatography on benzamidine-Sepharose 6B (Pharmacia
Biotech, Uppsala, Sweden). Both purified enzymes dis-
played the characteristic absorption spectra of highly
purified enzymes, with absorbance ratios Abs280/Abs450
between 5.3 and 5.8. To evaluate the presence of inactive
forms of the enzyme (desulfo and demolybdo), the activity-
to-flavin ratio (AFR) of the XO form was calculated,
dividing the absorbance change per minute at 295 nm by
the absorbance at 450 nm of the enzyme used in the assay
(200 was taken to be 100% active [31]). The final XO
concentration was determined spectrophotometrically
using e = 71,500 M–1 cm–1 at 450 nm for the oxidised
enzyme [32], and was corrected for the presence of inactive
molecules. The XO batches thus obtained did not have
xanthine:NAD+ oxidoreductase activity.
Preparation of the dehydrogenase form of XOR
from rat liver
XOR in its XD form was obtained through reversible
reduction of oxidised XO sulfhydryl groups. Purified XO
was incubated with 5 mM dithiothreitol, for 1–2 h, at
303 K, and then passed through a small G-25 column
(Pharmacia Biotech, Uppsala, Sweden) equilibrated in
100 mM tris(hydroxymethyl)aminomethane (Tris)–HCl
buffer, pH 7.8. Dithiothreitol treatment resulted in an 80–
85% decrease in the XO activity (xanthine:O2 oxidore-
ductase activity) and a dehydrogenase-to-oxidase ratio of
5–6 was achieved, as previously described [30]. Consid-
ering the intrinsic xanthine:O2 oxidoreductase activity of
the XD form [31, 33, 34], the XD batches thus prepared are
highly purified, with less than 5% irreversible XO con-
tamination.
Preparation of the deflavo-XD form of XOR
THe deflavo-XD form of XOR was prepared as described
by Branzoli and Massey [35].
Preparation of XO from butter milk
Lyophilised XO from butter milk, obtained from Sigma
Chemical Co. (Madrid, Spain), was desalted by gel filtra-
tion on a small G-25 column (Pharmacia Biotech, Uppsala,
Sweden) equilibrated in 100 mM Tris–HCl buffer, pH 7.8.
Purification of the XO form of XOR from human liver
XO was prepared from one sample (38 g) of human liver
(4 days after death), as described earlier for rat liver XO.
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However, the resulting enzyme sample displayed a com-
paratively low Abs280/Abs450 of 9.5.
Steady-state kinetics of NADH oxidation by XOR
The initial rates of NADH oxidation by both XD and XO
forms of XOR were measured following the decrease in
absorbance at 340 nm (e = 6,220 M–1 cm–1). The enzymes
were incubated with varying concentrations of NADH
(2.5–100 lM) in air-equilibrated 50 mM Tris–HCl buffer,
with 1 mM EDTA, pH 7.8. Each initial rate determination
was performed with three different enzyme batches, in
quintuplicate, except for bovine milk XO, for which only
one enzyme lot was assayed. The apparent kinetics
parameters were estimated by the direct linear method of
Eisenthal and Cornish-Bowden [36]. The values obtained
using the double-reciprocal plot agreed within a maximum




Steady-state kinetics of O2
•– formation by XOR
O2
•– formation during NADH oxidation by both XD and
XO forms of XOR was estimated as the superoxide
dismutase inhibitable reduction of cytochrome c [37]. The
reaction mixtures contained 50 mM Tris–HCl buffer, with
1 mM EDTA, pH 7.8, 100 lM ferricytochrome c and
varying concentrations of NADH (2.5–100 lM). The ini-
tial rates of O2
•– formation (determined in quintuplicate
and with three different enzyme batches) were evaluated by
the increase in absorbance at 550 nm (De = 21,000 M–1
cm–1) in the absence and in the presence of 2,500 U cm–3
superoxide dismutase. The apparent kinetics parameters
were estimated by the direct linear method of Eisenthal and
Cornish-Bowden [36]. The values obtained using the
double-reciprocal plot agreed within a maximum error





The percentage of oxygen one-electron reduction was
calculated as half of the ratio of the O2
•– production rate to
the NADH oxidation rate, with the initial rates being cal-
culated from the kinetics parameters determined.
Reductive titration of rat liver XOR and the deflavo-XD
form
Reductive titrations of both the XD and XO forms of rat
liver XOR with NADH were followed by EPR spectros-
copy at 20, 40, 60 and 100 K. The enzyme samples were
reduced anaerobically with NADH for 5 min in 50 mM
Tris–HCl buffer pH 7.8 at 293 K before being frozen.
Enzymes were also reduced with dithionite, for 30 min.
The samples were cooled with an Oxford Instruments
ESR900 liquid-helium cryostat, fitted with a temperature
controller. X-band EPR spectra were recorded using a
Bruker EMX 6/1 spectrometer, equipped with a dual-mode
ER4116DM cavity. The experimental conditions main-
tained an amplitude and a frequency of modulation of
0.405 mT and 100 kHz, respectively, 0.0635-mW micro-
wave power and a signal gain of 2.00 · 105 (with NADH)
or 2.00 · 104 (with dithionite). EPR spectra are presented
as the first derivative of absorption, in arbitrary units, and
g1, g2 and g3 factors stand for the low-field, medium-field
and high-field lines.
The FADH•, Mo(V), Fe/S I and Fe/S II EPR signals
were simulated individually with the SimFonia program
from Bruker and, subsequently, added together in different
proportions, until a good agreement between the simulated
and the experimental spectrum was observed. Spin quan-
tifications of the EPR signals were determined by double
integration of the first derivative of the spectra relative to
the spectrum of Cu2+-EDTA (3 mM), recorded under
nonsaturating conditions.
Results
Steady-state kinetics of NADH oxidation catalysed
by rat liver XOR
NADH oxidation, catalysed by both XD and XO forms of
rat liver XOR, was studied by following the disappearance
of NADH spectrophotometrically at 340 nm, in air-equil-
ibrated buffer at 298 K. The initial rates, measured at dif-
ferent NADH concentrations, are shown in Fig. 1. No
substrate inhibition was observed, and the experimental
data fitted well to the Michaelis–Menten equation, giving
the apparent kinetics parameters presented in Table 1.
NADH is a significantly better substrate for XD, with a
higher kcat
app and a lower Km
app, than XO. Similar assays were
performed in the presence of 50, 200 and 550 lM allopu-
rinol (a XOR inhibitor, which acts at the molybdenum
centre) and with enzyme batches with low AFR (73 and
96). Reaction profiles, identical to those of noninhibited
and 100% active enzymes, were obtained in all cases.
NADH oxidation was not observed in the presence of
deflavo-XD, confirming that NADH oxidation by XD oc-
curs at its flavin centre.
NADH oxidation catalysed by rat liver AO was also
studied spectrophotometrically and fluorimetrically, but the
oxidation rates were much slower, to enable accurate value
determinations.
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Steady-state kinetics of NADH oxidation catalysed
by bovine milk XO
For comparative purposes, NADH oxidation catalysed by
bovine milk XO was also studied and the initial rates for
different NADH concentrations were determined (Fig. 1).
To emphasise the differences in the kinetics between the rat
liver and the bovine milk enzymes, the rat liver XO and
XD data were fitted to hyperbolic curves, while the bovine
milk XO data presented were fitted to a straight line. As
can be observed, although the bovine milk XO showed no
saturation kinetics, the rat liver XO and XD forms are
better catalysts for NADH oxidation than the bovine milk
XO, in particular at lower and physiologically more
important NADH concentrations.
Steady-state kinetics of NADH oxidation catalysed
by human liver XO
NADH oxidation catalysed by human liver XO was studied
with an enzyme batch presenting a purification degree
lower than the ones recovered from rat liver. The apparent
values of Km (7.5 lM) and V (5.3 lM min
–1) were deter-





















































Fig. 1 NADH oxidation catalysed by both xanthine dehydrogenase
(XD) and xanthine oxidase (XO) forms of rat liver xanthine
oxidoreductase (XOR) and by bovine milk XO. Initial rates of
NADH oxidation, catalysed by rat liver XD (0.275 lM) and XO
(0.750 lM) forms and by bovine milk XO (0.750 lM), were
measured spectrophotometrically at 340 nm, in air-equilibrated
tris(hydroxymethyl)aminimethane (Tris)–HCl 50 mM buffer pH 7.8.
a The values represented for the rat liver XD and XO were from a
representative experiment and the hyperbolic curves were generated
with the apparent kinetics parameters given in Table 1 and estimated
by the direct linear plots shown in b and c




app (lM) kNADH (lM
–1 min–1)
For NADH oxidation
XD (rat liver) 29.2 ± 1.6 3.34 ± 0.34 8.73 ± 1.36
XO (bovine milk) Deviation from saturation kinetics
XO (rat liver) 9.38 ± 0.31 8.73 ± 0.44 1.07 ± 0.09
For O2
•– formation
XD (rat liver) 27.4 ± 1.0 3.27 ± 0.16 8.40 ± 0.73
XO (rat liver) 9.20 ± 0.18 8.40 ± 0.26 1.10 ± 0.06
AO (rat liver) 2.63 ± 0.30 5.13 ± 0.38 0.512 ± 0.096
The values shown are means (± standard deviation) of three independent experiments performed with three different enzyme batches
AO aldehyde oxidase, XD xanthine dehydrogenase, XO xanthine oxidase
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(Fig. 2). A kcat
app ‡ 13 min–1 was estimated, taking into ac-
count an XO concentration lower than 0.40 lM
(e450nm = 71,500 M
–1 cm–1) [32]. The human and rat liver
XO specificity constants for NADH are, therefore, of the
same magnitude: 1.73 and 1.07 lM–1 min–1, respectively.
Steady-state kinetics of O2
•– formation during NADH
oxidation catalysed by rat liver XOR
During NADH oxidation catalysed by both XD and XO
forms of rat liver XOR, O2 is reduced to O2
•– and H2O2.
The O2
•– formation, estimated as the superoxide dismutase
inhibitable reduction of cytochrome c, followed saturation
kinetics with no evidence of substrate inhibition (for 2.5–
100 lM NADH). The initial rates of O2
•– generation were
fitted to a Michaelis–Menten equation and the calculated
apparent kinetics parameters are shown in Table 1. Simi-
larly, it was observed that when NADH oxidation was
followed, the XD specificity constant for NADH was
higher (8.40 ± 0.73 lM–1 min–1) than that obtained for XO
(1.10 ± 0.06 lM–1 min–1). Accordingly, these results show
that the XD form is intrinsically more efficient at gener-
ating O2
•– than the XO form of XOR. It is important to note
that the values of the XO and XD kinetics constants for
NADH, determined via O2
•– production, were close to
those obtained via NADH oxidation. These results indicate
that, when the reductive substrate is NADH, the fraction of
O2
•–/H2O2 formed does not depend on its concentration.
This became evident when the percentages of oxygen one-
electron reductions were calculated and found to be
approximately constant for any NADH concentration
(Fig. 3). These results must be emphasised, since they
contradict those obtained for the bovine milk XO during
xanthine oxidation, in which the percentage of O2
•– gen-
erated decreases (25–35%) as the concentration of xanthine
increases [8, 9].
EPR spectral properties of reduced rat liver XOR
Since each of the redox centres of XOR is paramagnetic in
one of its oxidation states, the reduction profiles of FADH•,
Mo(V) and reduced Fe/S centres may be studied by EPR
spectroscopy [38]. To characterise the EPR signals of re-
dox centres of XD and XO forms of rat liver XOR, the
purified enzymes were reduced with an excess of dithionite
for 30 min, and the X-band EPR spectra were acquired at
different temperatures (20–100 K). The EPR spectra of the
dithionite-reduced XD form (Fig. 4) and XO form (not
shown) were qualitatively similar and showed the signals
from FADH•, two Fe/S and Mo(V) centres. These signals
were simulated individually at 20 and 100 K (Fig. 5) and
the EPR parameters found are presented in Tables 2 and 3.
The signals obtained are closely related to those observed
and described for bovine milk XO and for avian liver XD
[39–45]. Both active and desulfo enzymes are reduced

































Fig. 2 NADH oxidation catalysed by human liver XO. Initial rates of
NADH oxidation, catalysed by human liver XO, were measured
spectrophotometrically at 340 nm, in air-equilibrated Tris–HCl
50 mM buffer pH 7.8. The hyperbolic curve was generated with the
parameters given in Table 1. The apparent kinetics parameters were
















Fig. 3 Percentage of one-electron oxygen reduction, catalysed by
both XD and XO forms of rat liver XOR during NADH oxidation.
The percentage of one-electron oxygen reduction was calculated to be
half of the ratio of the O2
•– formation rate to the NADH oxidation
rate, the initial rates calculated from the parameters presented in
Table 1
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signal was simulated as a mixture of slow and rapid type 1.
The isotropic splitting (D = 1.2 mT) of the Mo(V) signals,
observed at temperatures of or below 60 K (with or without
the Fe/S II reduced), results from the magnetic interaction
between the Mo(V) and the Fe/S I centre, as observed by
Lowe et al. [46] with bovine milk XO. Also, no interactions
were detected between Mo(V) and Fe/S II or between FAD
and Mo(V).
Both XD and XO forms of rat liver XOR were also
reduced with increasing quantities of NADH. The EPR
spectra at 20 and 100 K of NADH-reduced XD (Fig. 6)
and XO (not shown) were qualitatively similar to the
dithionite-reduced spectra. The EPR signals from NADH-
reduced enzymes were simulated individually and the EPR
parameters determined are shown in Tables 2 and 3. The
simulation of the Mo(V) signal, as a mixture of slow and
rapid type-1 signals, was consistent with the known
simultaneous reduction by NADH of active and desulfo
enzymes, via the flavin (with subsequent reduction of
Mo(V) [47]. In addition, the Mo(V) signals were also found
to split (D = 1.2 mT) in the presence of the Fe/S I centre
(at temperatures below 60 K). The spectra were, however,
quantitatively quite different, with the extent of the XD
reduction being higher than that of XO. Figure 7 summa-
rises the results of the reductive titration experiments.
The spectra of deflavo-XD in the presence of NADH
display no EPR signals (with enzyme-to-NADH molar
ratios of 1:500 or less), indicating that the NADH reduction
of XD occurs via FAD. In the presence of dithionite, the
deflavo enzyme was reduced and the resulting EPR spectra
were similar to those of dithionite-reduced XD and XO
(Fig. 8), showing the Fe/S centres and Mo(V) signals, but
without the flavin signal.
Discussion
NADH oxidase activity of XOR has long been recognised
[48–50], but only recently was its potential as a source of
ROS realised. Most interest was mainly focused on free-
radical metabolism, mediated through hypoxanthine/xan-
thine oxidation by XO, in biochemical mechanisms asso-
ciated with a wide variety of human diseases. This ‘‘new’’
ROS-generating pathway, of XOR and NADH, must then
be reevaluated in those clinical conditions where an in-
crease in NADH is expected, such as in diseases where
hypoxic and reperfusion cycles exist, in ethanol hepato-
toxicity and in diabetes [12, 14, 51–54].
To characterise this potential mammalian liver source of
ROS, NADH oxidase activity was studied using both XD
and XO forms of rat liver XOR. In addition to the fact that
mammalian liver enzymes have been poorly studied, other
reasons justify the further investigation of liver XOR. The
specific activity of human XOR is high in liver and when
liver damage occurs, there is an increase in the levels of
circulating enzyme, which can bind to vascular endothe-
lium, causing injury [14]. For the diseases referred to
above, it seemed more meaningful to carry out studies with
liver enzymes than with milk enzymes. Rat liver enzymes,
for instance, are kinetically quite different from the human
milk enzymes, which show little XOR activity [24], thus
hindering comparative studies between xanthine and
NADH (physiological reducing substrates) as a ROS
source. In addition, a direct comparison between XD and
XO forms from the same source can be made. Furthermore,
the recently reported XOR-catalysed production of •NO, in
the presence of nitrite, with either NADH or xanthine as
reducing substrates under anaerobic conditions, undoubt-
edly contributed to further stimulate interest in the physi-









Fig. 4 Electron paramagnetic resonance (EPR) spectra of the
dithionite-reduced XD form of rat liver XOR. The enzyme (40 nmol)
was treated anaerobically with sodium dithionite (400 nmol) for
30 min, and spectra were recorded at the temperatures indicated.
Other experimental conditions were as follows: microwave fre-
quency, 9.65 GHz; microwave power, 0.0635 mW; modulation
amplitude, 4.05 G; receiver gain, 2.00 · 104




















Fig. 5 Simulation of the EPR
spectra of the dithionite-reduced
XD form of rat liver XOR at 20
and 100 K. Each EPR signal of
dithionite-reduced XD, at 20
and 100 K, was simulated
individually with the parameters
given in Tables 2 and 3. The
experimental spectra were
recorded with the experimental
conditions indicated in Fig. 3
Table 2 Electron paramagnetic resonance (EPR) signal parameters of the Fe/S II, Fe/S I and FADH• from NADH and dithionite-reduced rat
liver XD and XO (at 20 K)
Signal Reducing substrate Enzyme g1[line width (mT)] g2[line width (mT)] g3[line width (mT)]
Fe/S II NADH XD or XO 2.0945 (3.00) 1.9910 (2.50) 1.8895 (2.25)
Dithionite XD 2.0945 (4.00) 1.9910 (2.50) 1.8910 (2.50)
Dithionite XO 2.1120 (5.50) 1.9910 (4.50) 1.8910 (4.00)
Fe/S I NADH XD or XO 2.0210 (1.90) 1.9315 (1.57) 1.8990 (2.375)
Dithionite XD 2.0210 (1.90) 1.9320 (1.57) 1.8995 (2.37)
Dithionite XO 2.0215 (1.90) 1.9327 (1.57) 1.8987 (2.37)
Signal Reducing substrate Enzyme g[line width (mT)]
FADH• NADH XD or XO 2.0055 (3.60)
Dithionite XD 2.0053 (4.80)
Dithionite XO 2.0060 (1.95)
FADH reduced flavin adenine dinucleotide, g line width
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•NO synthase, can be an important source of •NO in
ischaemia, thus promoting the •NO-induced vasodilatation
[17, 18].
EPR spectra of NADH-reduced XD and XO were quite
useful in order to define the spectral parameters of the EPR
signals detected for reduced iron–sulfur centres and Mo(V)
species. The data make quite clear, as discussed below, that
NADH efficiently reduces XD but a large excess of NADH
is needed to efficiently reduce XO.
The kinetics studies carried out to compare the NADH
oxidation catalysed by the rat liver XD and XO forms of rat
liver XOR demonstrated that both enzymes do catalyse
NADH oxidation with O2
•– generation. It is, however,
significant that the XD form is a better catalyst for NADH
oxidation than is the XO form, having a higher specificity
constant, whether determined by NADH consumption
(8.73 ± 1.36 and 1.07 ± 0.09 lM–1 min–1, respectively) or
by O2
•– formation (8.40 ± 0.73 and 1.10 ± 0.06 lM–1
min–1, respectively).
The percentage of one-electron oxygen reduction ca-
talysed by rat liver XOR was found to be constant as the
NADH concentration increased by 50%, indicating that one
molecule of O2
•– is formed per NADH molecule. These
results are clearly different from those described for xan-
thine oxidation by XO, where the fraction of O2
•– formed
decreases as xanthine concentration increases [8, 9, 56, 57].
Therefore, the chemical equation for the NADH oxidation
reaction can be written as
2NADHþ 3O2 ! 2NADþ þ 2O2 þ H2O2: ð1Þ
In addition, it must be emphasised that the kinetics
parameters obtained for human liver XO towards NADH
oxidation were found to be very similar to those of XO
forms of rat liver XOR. Considering the important physi-























Fig. 6 EPR spectra of the XD
form of rat liver XOR reduced
with increasing quantities of
NADH at 20 and 100 K. The
enzyme (40 nmol) was reduced
anaerobically, for about 5 min,
with NADH, at the XD-to-
NADH ratios indicated, and the
EPR spectra were recorded at 20
and 100 K. Other experimental
conditions were as follows:
microwave frequency,
9.65 GHz; microwave power,
0.0635 mW; modulation
amplitude, 4.05 G; receiver
gain, 2.00 · 105
Fig. 7 Anaerobic titration of both XD and XO forms of rat liver
XOR with NADH. The enzymes (40 nmol) were reduced anaerobi-
cally, for about 5 min, with increasing quantities of NADH, and the
EPR spectra were recorded at 20 and 100 K. The FADH•, Mo(V) and
Fe/S EPR signals were simulated individually (with the parameters
given in Tables 2 and 3) and then added together, in different
proportions, until good agreement between the simulation sum and
the experimental spectrum was observed. Finally, the individual
signals were quantified by their areas (double integration of the
simulated signal) using a 3 mM Cu2+–EDTA standard. FADH
reduced flavin adenine dinucleotide
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sults enable us to use rat liver XOR as a first approach in
studies whose results are intended to be extrapolated to the
human enzyme.
In agreement with the kinetics parameters obtained for
both enzyme forms, much higher intensity EPR spectra
were observed with NADH-reduced XD than with XO.
While FAD removal completely hampers enzyme reduc-
tion by NADH (no EPR signals were observed) and abol-
ishes NADH oxidase activity, the kinetics reaction profiles
obtained with inactive (desulfo and demolybdo) and allo-
purinol-inhibited enzymes were identical to those of native
enzymes. These results show that the NADH reduction of
rat liver XOR occurs via FAD and that alterations at the
molybdenum centre do not affect the NADH oxidation
kinetics.
With NADH as reducing substrate, the XD form is also
more efficient than XO in catalysing the reduction of nitrite
to •NO [17]. This fact is particularly relevant in vivo, since
the XD form is the predominant form in vivo.
Some studies with xanthine as a reducing substrate were
carried out (data not shown), and demonstrated that rat
liver XD is a better O2
•– source than XO, as previously
described [1, 33, 55]. The dehydrogenase form of liver
XOR is thus intrinsically more efficient at generating O2
•–
than the oxidase form, independently of the reducing
substrate. These are remarkable results, in light of the
common association of ROS-mediated damage with oxi-
dase enzymes. Therefore, XO is not essential for XOR-
catalysed generation of ROS, overcoming the increasingly
questioned conversion of XD to XO.
Many pathological conditions arise from free-radical
oxidation of DNA, proteins and lipids, and the products of
lipid peroxidation; in particular, aldehydes, directly or
indirectly, affect many functions integral to cellular
homeostasis [58]. Taking into account the ability of XOR
to catalyse O2
•–/H2O2 generation, it is expected that XOR
may induce the peroxidation of lipids. In fact, we have
shown that rat liver XOR can promote the oxidation of
lipids during NADH:O2 and xanthine:O2 turnover [59]. In
addition, higher peroxidation extents were observed in the
presence of NADH, when compared with equimolar con-
centrations of xanthine, and the rat liver XD form was
found to be the most efficient at promoting this oxidative
process. Compared with XOR, AO seems to play a minor
role in NADH-dependent liposomal lipid damage, which is
in agreement with the comparatively low values of the
kinetics parameters found for O2
•– formation.
Moreover, a new XOR-dependent route for the genera-
tion of peroxynitrite, a strong inflammatory oxidant, was
described [19]. Both •NO and O2
•– can be produced by
XOR, but the efficiency of ONOO– production depends on
the presence or absence of superoxide dismutase and on the
rate of O2
•– generation. Our results have shown that the XD
form of rat liver XOR is more effective at generating O2
•–
than is the XO form. Therefore, following the same rea-
soning as Godberg et al. [19], in the presence of oxygen,
the XD form will have fewer electrons available for the
reduction of nitrite than will XO, and it will generate less
ONOO–. This condition is more consistent with the likely
role of the predominant in vivo XD form in physiological
function.
On the whole, we conclude that XOR can be a source of
both ROS and reactive nitrogen species, which can induce
destructive and useful effects, but the physiological and
pathological implications of this complex enzyme are still
not completely clarified.
It is worth noting that our results, obtained with rat liver
XOR and bovine milk XO, show that enzymes from dif-
ferent sources have different kinetics properties. Never-
theless, the kinetics parameters of human liver XO for
NADH oxidation were, indeed, very similar to those of rat








Fig. 8 EPR spectra of the dithionite-reduced deflavo-XD form of rat
liver XOR. The enzyme (24 nmol) was treated anaerobically with
sodium dithionite (400 nmol) for 30 min, and the spectra were
recorded at the temperatures indicated. Other experimental conditions
were as follows: microwave frequency, 9.45 GHz; microwave power,
2.01 mW; modulation amplitude, 10.145 G; receiver gain, 2.50 · 104
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applications of rat liver enzyme XOR as a model for the
human liver enzymes.
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